PFIZER VACCINE
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
Rate...
Relative measure of effect (incidence rate ratio):
(8 cases/2,214 person-years) / (162 cases/2,222 person-years)
= 0.05
or a 95% less rate of occurrence of #COVID19 cases for vaccine vs. placebo pic.twitter.com/Qg1Em914Cv
THREAD
Breaking down the “efficacy” and safety of the #COVID19 vaccines if applied to the population
MODERNA VACCINE
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
Only RISK- (& not rate-) related measures are provided for Moderna...
Relative measure of effect (incidence risk ratio):
(11 cases/14,134 persons) / (185 cases/14,073 persons)
= 0.06
or a 94% less risk of occurrence of #COVID19 cases for vaccine vs. placebo pic.twitter.com/xiZPi6QXH8
ASTRAZENECA VACCINE
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
Rate...
Relative measure of effect (incidence rate ratio):
(44.1 cases/1,000 person-years) / (149.2 cases/1,000 person-years)
= 0.296
or a 70.4% less rate of occurrence of #COVID19 cases for vaccine vs. placebo pic.twitter.com/OJD6xeOksq
^ Are those 0.13% less #COVID19 cases worth the development of an expected 20.7% or 1,614,000,000 related adverse events (of which 1,443,042 would be serious) over a week (and completely unknown magnitude of related adverse events beyond this first week)?https://t.co/w6VSAuFZcg pic.twitter.com/Cl1hVx5XT0
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
^ Are 1.2% less cases in 2 months worth development of 8.2% or 637,971,682 related adverse events (of which 71,913,072 would require medical attention and 3,081,988 be serious) over 28 days (and unknown magnitude of related adverse events beyond 28 days)?https://t.co/j0uD21d9iK pic.twitter.com/sE0KLjkSR0
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
^ Are those 1.2% less #COVID19 cases worth the development of an expected 0.7% or 62,400,000 adverse events (of which 54,600,000 would be serious) over ~6 weeks (and completely unknown magnitude of adverse events beyond these first ~6 weeks)?https://t.co/nUliSrTkWi pic.twitter.com/okFMzqBL5d
— Paradigm Shift Platforms (@Shift_Platforms) January 26, 2021
Given that only ~1 in 5 #COVID19 cases require hospitalization, this means that only ~20% of the already minute levels of decreases provided by vaccines in the occurrence of #COVID19 would prevent #COVID19 leading to hospitalizations...
https://t.co/UD5pIQjIY2
* Pfizer vaccine would lead to only ~0.03% less #COVID19 hospitalizations over 1 week
* Moderna vaccine would lead to only ~0.24% less #COVID19 hospitalizations over 2 months
* AstraZeneca vaccine would lead to only ~0.24% less #COVID19 hospitalizations over 6 weeks
* Pfizer vaccine would cause 1,443,042 serious adverse events over 1 week
* Moderna vaccine would cause 3,081,988 serious adverse events over 28 days
* AstraZeneca vaccine would lead to 54,600,009 serious adverse events over 6 weeks
https://t.co/9Ckp1Fy53h
Further, niacin is a safe, natural vitamin; readily available; & would cost <1 cent a gram in bulk https://t.co/rAFMIHzUeA
Sufficient niacin supply: the missing puzzle piece to COVID-19, and beyond?https://t.co/gHcfOcekcf
— Paradigm Shift Platforms (@Shift_Platforms) January 20, 2021
Sensational results are being observed per below PROTOCOL
If NIACIN has helped you/loved one for #COVID19 (or anything else), please elaborate on the experience in comments below https://t.co/BthaRndiWV pic.twitter.com/yFsP6A3VDs
Beyond brief follow-up, they could very well even exasperate burden of disease outcome (i.e. #COVID19 hospitalizations) that they intend to & do initially—albeit meaninglessly—protect against!
https://t.co/ROir4ebMjB
85% efficacy does not mean 85% less cases. Stop misleading the public with your influence by whether carelessly or intentionally avoiding dissemination of actually interpretable communications of public health impact.
— Paradigm Shift Platforms (@Shift_Platforms) January 30, 2021
See through here https://t.co/QyXBgDn4zx
More from All
You May Also Like
@NBA @StephenKissler @yhgrad 1. From Day 1, SARS-COV-2 was very well adapted to humans .....and transgenic hACE2 Mice
1. From Day 1, SARS-COV-2 was very well adapted to humans .....and transgenic hACE2 Mice
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) January 30, 2021
"we generated a mouse model expressing hACE2 by using CRISPR/Cas9 knockin technology. In comparison with wild-type C57BL/6 mice, both young & aged hACE2 mice sustained high viral loads... pic.twitter.com/j94XtSkscj
@NBA @StephenKissler @yhgrad 2. High Probability of serial passaging in Transgenic Mice expressing hACE2 in genesis of SARS-COV-2
1. High Probability of serial passaging in Transgenic Mice expressing hACE2 in genesis of SARS-COV-2!
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) January 2, 2021
2 papers:
Human\u2013viral molecular mimicryhttps://t.co/irfH0Zgrve
Molecular Mimicryhttps://t.co/yLQoUtfS6s https://t.co/lsCv2iMEQz
@NBA @StephenKissler @yhgrad B.1.1.7 has an unusually large number of genetic changes, ... found to date in mouse-adapted SARS-CoV2 and is also seen in ferret infections.
https://t.co/9Z4oJmkcKj
@NBA @StephenKissler @yhgrad We adapted a clinical isolate of SARS-CoV-2 by serial passaging in the ... Thus, this mouse-adapted strain and associated challenge model should be ... (B) SARS-CoV-2 genomic RNA loads in mouse lung homogenates at P0 to P6.
https://t.co/I90OOCJg7o